Business Context and Reporting Period
This Form 8-K filing by NantKwest, Inc. (NK) reports a significant executive leadership change effective October 26, 2020. The filing details the appointment of Richard Adcock as Chief Executive Officer and the concurrent resignation of Dr. Patrick Soon-Shiong from the CEO role, with Dr. Soon-Shiong continuing as Executive Chair of the Board.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
- Annual Base Salary: $750,000
- Target Discretionary Bonus: 50% of base salary ($375,000 annually), prorated for 2020.
- Guaranteed Bonus (2021): At least 50% of the target bonus ($187,500).
- Equity Grant: Option to purchase 1,000,000 shares of common stock.
- Severance: 12 months of base salary ($750,000) upon termination without Cause.
- Benefit Reimbursement: Approximately $30,000 annually for life insurance policies.
Material Changes
The primary material change is the transition of CEO leadership. Richard Adcock, formerly CEO of Verity Health and holding various executive roles at Sanford Health and GE Healthcare, replaces Dr. Patrick Soon-Shiong. The filing notes that Verity Health was previously affiliated with Dr. Soon-Shiong until 2018.
Outlook, Risks, and Unusual Items
Equity Vesting Schedule: The 1,000,000 stock options granted to Mr. Adcock vest as follows: 25% (250,000 options) on January 1, 2021, and the remaining 75% in equal annual installments on November 1, 2021, 2022, and 2023. The exercise price will be the fair market value on the grant date.
Employment Terms: The offer letter provides for at-will employment with no specific term. Bonus payments are contingent on Mr. Adcock remaining employed through the payment date. Severance is contingent on signing a release of claims.
Risks and Contingencies: The filing states Mr. Adcock has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, and no family relationships exist between him and current directors or officers.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 1,000,000 stock options once the Board formally approves the grant.
- Review the full text of the offer letter (to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2020) for complete terms.
- Monitor the company's cash burn rate given the new annual fixed compensation obligation of approximately $1.125 million (salary + target bonus) plus equity dilution.
- Confirm the status of Dr. Patrick Soon-Shiong's continued role as Executive Chair and any associated compensation changes.